<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562194</url>
  </required_header>
  <id_info>
    <org_study_id>VS-003/D</org_study_id>
    <nct_id>NCT04562194</nct_id>
  </id_info>
  <brief_title>NeVa ONE Registry Study</brief_title>
  <official_title>NEVA ONE One-Pass Reperfusion With the NeVa Stent-Retriever EMEA Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vesalio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vesalio</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label study designed to assess the safety, performance and efficacy of&#xD;
      thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent&#xD;
      retrievers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, multi-center registry designed to assess the safety,&#xD;
      performance and efficacy of the NeVa stent retriever in the treatment of large vessel&#xD;
      occlusion strokes. Up to 600 subjects will be enrolled at up 30 sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Pass Success Rate</measure>
    <time_frame>post-procedure day 0</time_frame>
    <description>The primary study endpoint is the first pass success rate with the NeVa device defined as eTICI score ≥ 2B &amp; eTICI ≥2C</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NeVa Stent Retriever</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeVa Stent Retriever</intervention_name>
    <description>mechanical neurothrombectomy</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Only subjects already treated with the NeVa thrombectomy devices can be considered for&#xD;
        enrollment.&#xD;
&#xD;
          1. Age ≥18&#xD;
&#xD;
          2. NIHSS score ≥ 6&#xD;
&#xD;
          3. Pre-stroke mRS score ≤ 1&#xD;
&#xD;
          4. Intracranial arterial occlusion of the distal intracranial carotid artery or middle&#xD;
             cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery&#xD;
             (PCA), basilar artery, or vertebral artery demonstrated with DSA.&#xD;
&#xD;
          5. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as&#xD;
             time last known well [TLKW])&#xD;
&#xD;
          6. Imaging Inclusion Criteria:&#xD;
&#xD;
             The patient should have confirmed LVO and salvageable penumbra. Any automated software&#xD;
             for determine the volume of viable tissue is acceptable. patient selection should&#xD;
             follow the following guidelines:&#xD;
&#xD;
               -  ASPECTS 6-10 if treatment started 0-6 hours from TLKW&#xD;
&#xD;
               -  ASPECTS 8-10 if treatment started 6-24 hours from TLKW&#xD;
&#xD;
               -  Ischemic core ≤ 50 cc&#xD;
&#xD;
          7. Subject or legal representative is able and willing to give informed consent within 72&#xD;
             hours after the intervention (may use independent physician consent in this timeframe&#xD;
             and gain subject or legal representative consent later than 72 hours).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-existing medical neurological or psychiatric disease that would confound the&#xD;
             neurological or functional evaluations, e.g. dementia with prescribed&#xD;
             anti-cholinesterase inhibitor (e.g. Aricept).&#xD;
&#xD;
          2. Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing&#xD;
             myocardial infarction, concern for pre- treatment pulmonary aspiration.&#xD;
&#xD;
          3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories&#xD;
&#xD;
          4. Cerebral vasculitis&#xD;
&#xD;
          5. History of severe allergy to contrast medium.&#xD;
&#xD;
          6. Known allergy to NeVa materials (nitinol, stainless steel)&#xD;
&#xD;
          7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis&#xD;
&#xD;
          8. Systemic infection&#xD;
&#xD;
          9. Significant mass effect with midline shift&#xD;
&#xD;
         10. Evidence of intracranial tumor (except small meningioma)&#xD;
&#xD;
         11. Inability to deploy NeVA device for at least one pass for any other reason&#xD;
&#xD;
         12. Life expectancy less than 6 months&#xD;
&#xD;
         13. Any other condition that, in the opinion of the investigator, precludes an&#xD;
             endovascular procedure or poses a significant hazard to the subject if an endovascular&#xD;
             procedure was performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen Calderon</last_name>
    <phone>615-206-7788</phone>
    <email>kcalderon@vesalio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Espanol de Mendoza</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Petra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niguarda Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edoardo Boccardi</last_name>
      <phone>+39 3516775140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Abu Dhabi</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Shelby, MD</last_name>
      <phone>+971 2 659 0200</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Italy</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombus</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

